Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:
• Age ≥65 years
• Histologically confirmed stage IV NSCLC
• Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
• Treated with at least ONE cycle of first-line chemotherapy
Locations
Other Locations
Hong Kong Special Administrative Region
Queen Mary Hospital, The University of Hong Kong
RECRUITING
Hong Kong
Malaysia
Hospital Wanita dan Kanak-Kanak Sabah
RECRUITING
Kota Kinabalu
Universiti Malaya Medical Centre
RECRUITING
Kuala Lumpur
Hospital Tengku Ampuan Afzan
RECRUITING
Kuantan
Contact Information
Primary
Mau Ern Poh, MBBS
ernestpoh@um.edu.my
+60379494422
Backup
Danouska Bala Krishnan
danouska@ummc.edu.my
+603-79492351
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 150
Treatments
Normal dose group
Patients receiving standard dose of chemotherapy
Dose reduction group
Patients receiving lower doses of chemotherapy
Related Therapeutic Areas
Sponsors
Leads: University of Malaya